CYP19A1 and breast carcinoma: While this idea requires further exploration, this hypothesis is interesting to note in light of the recently published case study in which a patient with late stage MCL1-amplified ERα+ breast cancer treated with aromatase inhibition (anastrozole) and RAD001/everolimus achieved a pathological complete response [42].